Trial Profile
SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Biotin (Primary)
- Indications Charcot-Marie-Tooth disease; Demyelinating disorders; Polyneuropathy
- Focus Therapeutic Use
- Acronyms SERENDEM
- Sponsors MedDay Pharmaceuticals
- 29 Oct 2020 Status changed from recruiting to completed.
- 22 Nov 2016 New trial record